$LAB
STANDARD BIOTOOLS INC.

2021 Q1 Form 10-Q Financial Statement

#000162828021009552 Filed on May 07, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $32.79M $27.62M
YoY Change 18.75% -8.28%
Cost Of Revenue $13.75M $11.17M
YoY Change 23.12% -14.87%
Gross Profit $19.04M $13.00M
YoY Change 46.45% -23.47%
Gross Profit Margin 58.06% 47.08%
Selling, General & Admin $27.61M $22.70M
YoY Change 21.65% -0.57%
% of Gross Profit 144.99% 174.55%
Research & Development $10.75M $8.699M
YoY Change 23.61% 3.91%
% of Gross Profit 56.47% 66.91%
Depreciation & Amortization $3.917M $4.060M
YoY Change -3.52% 1.75%
% of Gross Profit 20.57% 31.23%
Operating Expenses $52.11M $42.56M
YoY Change 22.45% -3.97%
Operating Profit -$19.32M -$14.94M
YoY Change 29.3% 5.18%
Interest Expense $887.0K $900.0K
YoY Change -1.44% -66.68%
% of Operating Profit
Other Income/Expense, Net -$285.0K -$818.0K
YoY Change -65.16% -269.01%
Pretax Income -$20.49M -$16.66M
YoY Change 23.0% -34.47%
Income Tax -$1.700M -$700.0K
% Of Pretax Income
Net Earnings -$18.82M -$15.98M
YoY Change 17.78% -37.25%
Net Earnings / Revenue -57.39% -57.86%
Basic Earnings Per Share -$0.25
Diluted Earnings Per Share -$0.25 -$0.23
COMMON SHARES
Basic Shares Outstanding 74.71M shares 70.45M shares
Diluted Shares Outstanding 74.71M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.74M $48.50M
YoY Change 2.56% -35.42%
Cash & Equivalents $49.74M $34.99M
Short-Term Investments $13.50M
Other Short-Term Assets $9.279M $3.200M
YoY Change 189.97% -3.03%
Inventory $21.89M $16.29M
Prepaid Expenses
Receivables $15.41M $14.41M
Other Receivables $0.00 $0.00
Total Short-Term Assets $96.33M $82.43M
YoY Change 16.85% -26.05%
LONG-TERM ASSETS
Property, Plant & Equipment $23.78M $8.143M
YoY Change 192.08% -1.11%
Goodwill $106.5M $106.3M
YoY Change 0.12% 2.13%
Intangibles $37.00M $48.61M
YoY Change -23.89% -10.97%
Long-Term Investments
YoY Change
Other Assets $4.386M $5.204M
YoY Change -15.72% -11.04%
Total Long-Term Assets $208.9M $207.8M
YoY Change 0.52% 15.46%
TOTAL ASSETS
Total Short-Term Assets $96.33M $82.43M
Total Long-Term Assets $208.9M $207.8M
Total Assets $305.2M $290.2M
YoY Change 5.16% -0.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.55M $9.440M
YoY Change 32.97% 36.1%
Accrued Expenses $15.04M $6.456M
YoY Change 132.92% 29.17%
Deferred Revenue $14.22M $12.67M
YoY Change 12.28% 2.77%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.53M $35.36M
YoY Change 51.37% 3.46%
LONG-TERM LIABILITIES
Long-Term Debt $53.84M $53.90M
YoY Change -0.12% 8.23%
Other Long-Term Liabilities $1.374M $461.0K
YoY Change 198.05% -18.26%
Total Long-Term Liabilities $1.374M $461.0K
YoY Change 198.05% -18.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.53M $35.36M
Total Long-Term Liabilities $1.374M $461.0K
Total Liabilities $182.3M $148.7M
YoY Change 22.55% 36.19%
SHAREHOLDERS EQUITY
Retained Earnings -$695.6M -$639.7M
YoY Change 8.73% 9.48%
Common Stock $75.00K $71.00K
YoY Change 5.63% 2.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $122.9M $141.5M
YoY Change
Total Liabilities & Shareholders Equity $305.2M $290.2M
YoY Change 5.16% -0.42%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$18.82M -$15.98M
YoY Change 17.78% -37.25%
Depreciation, Depletion And Amortization $3.917M $4.060M
YoY Change -3.52% 1.75%
Cash From Operating Activities -$12.90M -$4.295M
YoY Change 200.37% -78.66%
INVESTING ACTIVITIES
Capital Expenditures $6.923M $1.030M
YoY Change 572.14% 287.22%
Acquisitions $0.00 $5.154M
YoY Change -100.0%
Other Investing Activities $2.000M $18.49M
YoY Change -89.18% -294.84%
Cash From Investing Activities -$4.923M $17.46M
YoY Change -128.2% -278.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $501.0K $0.00
YoY Change
Cash From Financing Activities -$1.026M -$503.0K
YoY Change 103.98% -442.18%
NET CHANGE
Cash From Operating Activities -$12.90M -$4.295M
Cash From Investing Activities -$4.923M $17.46M
Cash From Financing Activities -$1.026M -$503.0K
Net Change In Cash -$18.78M $12.33M
YoY Change -252.27% -141.43%
FREE CASH FLOW
Cash From Operating Activities -$12.90M -$4.295M
Capital Expenditures $6.923M $1.030M
Free Cash Flow -$19.82M -$5.325M
YoY Change 272.28% -73.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001162194
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201613Member
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P9M
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q4 us-gaap Assets Current
AssetsCurrent
117663000 USD
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-34180
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
FLUIDIGM CORP
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0513190
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2 Tower Place, Ste 2000
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco,
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2021Q1 dei City Area Code
CityAreaCode
650
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
266-6000
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021Q1 dei Trading Symbol
TradingSymbol
FLDM
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74962847 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49744000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68520000 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
356000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
356000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15412000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25423000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
21892000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
19689000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9279000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4031000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
96327000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23784000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17531000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
37245000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
38114000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4386000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4680000 USD
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
37000000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
40206000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
106456000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
106563000 USD
CY2021Q1 us-gaap Assets
Assets
305198000 USD
CY2020Q4 us-gaap Assets
Assets
324757000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
12552000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9220000 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8693000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13787000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3025000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2973000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15037000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14794000 USD
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
14222000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13475000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
53529000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
54249000 USD
CY2021Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
53837000 USD
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
54224000 USD
CY2021Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
6732000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
8697000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37419000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38178000 USD
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7202000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7990000 USD
CY2021Q1 fldm Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
22167000 USD
CY2020Q4 fldm Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
21036000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1374000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1333000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
182260000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
185707000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74963000 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74963000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74543000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74543000 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
75000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
75000 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
818776000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
815624000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-331000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14942000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
112000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-695582000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-676761000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
122938000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
139050000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305198000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
324757000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32794000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27617000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10753000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8699000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27608000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22695000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
52114000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
42559000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19320000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
887000 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
900000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-285000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-818000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20492000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16660000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1671000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-680000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18821000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-15980000 USD
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74707000 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70458000 shares
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18821000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-15980000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-443000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-303000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-443000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-303000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19264000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16283000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
139050000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-525000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3677000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18821000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-443000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
122938000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
153612000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-146000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2364000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2049000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-15980000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-303000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
141496000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18821000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18821000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-15980000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3677000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2366000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2983000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2968000 USD
CY2021Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
934000 USD
CY2020Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
1092000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
132000 USD
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
140000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
151000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
380000 USD
CY2021Q1 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
315000 USD
CY2020Q1 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
195000 USD
CY2021Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
12000 USD
CY2020Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-116000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9843000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4730000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2896000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2280000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2763000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-112000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3363000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3124000 USD
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
156000 USD
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1040000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-9987000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2066000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12901000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4295000 USD
CY2021Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
CY2020Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
5154000 USD
CY2021Q1 fldm Proceeds From Research And Development Grant
ProceedsFromResearchAndDevelopmentGrant
2000000 USD
CY2020Q1 fldm Proceeds From Research And Development Grant
ProceedsFromResearchAndDevelopmentGrant
0 USD
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
0 USD
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
23644000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6923000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1030000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4923000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17460000 USD
CY2021Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
501000 USD
CY2020Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
525000 USD
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
146000 USD
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2020Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
357000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1026000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-503000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-331000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18776000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12331000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69536000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23736000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50760000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36067000 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
44000 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
44000 USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1200000 USD
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
87000 USD
CY2021Q1 fldm Non Cash Right Of Use Assets And Lease Liabilities
NonCashRightOfUseAssetsAndLeaseLiabilities
0 USD
CY2020Q1 fldm Non Cash Right Of Use Assets And Lease Liabilities
NonCashRightOfUseAssetsAndLeaseLiabilities
35465000 USD
CY2021Q1 fldm Asset Retirement Obligations Incurred But Not Yet Paid
AssetRetirementObligationsIncurredButNotYetPaid
324000 USD
CY2020Q1 fldm Asset Retirement Obligations Incurred But Not Yet Paid
AssetRetirementObligationsIncurredButNotYetPaid
303000 USD
CY2021Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
Certain prior period amounts in the condensed consolidated financial statements were reclassified to conform with the current period presentation. These reclassifications were immaterial and did not affect prior period total assets, total liabilities, stockholders’ equity, total revenue, total costs and expenses, loss from operations or net loss.
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. The full extent to which the COVID-19 pandemic impacts our business, results of operations and financial condition will depend on numerous evolving factors including, but not limited to, the magnitude and duration of the pandemic, the extent to which it will impact worldwide macroeconomic conditions, including the speed of recovery, and governmental and business reactions to the pandemic. We assessed certain accounting matters that generally require consideration of forecasted financial information, including the unknown impact of COVID-19 as of March 31, 2021. These accounting matters included, but were not limited to, our allowance for doubtful accounts and credit losses, inventory and related reserves and the carrying value of goodwill and other long-lived assets.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from these estimates and could have a material adverse effect on our condensed consolidated financial statements.</span></div>
CY2020Q1 us-gaap Legal Fees
LegalFees
400000 USD
CY2021Q1 fldm Product Warranty Term
ProductWarrantyTerm
P1Y
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business and Credit Risk</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist of cash, cash equivalents, investments, and accounts receivable. Our cash, cash equivalents, and investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and investments are financial instruments that potentially subject us to concentrations of risk. Under our investment policy, we invest primarily in securities issued by the U.S. government. The goals of our investment policy, in order of priority, are as follows: preserve capital, meet liquidity needs, and optimize returns. </span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally do not require collateral to support credit sales. To reduce credit risk, we perform credit evaluations of our customers. One customer from whom we derived product revenue exceed</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed 10% of revenue for the three months ended March 31, 2021. License revenue, recognized as part of a settlement agreement with a party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">who is not a regular customer, exceeded 10% of total revenue for the three months ended March 31, 2020. No other customer represented more than 10% of revenue during the three months ended March 31, 2021 or during the same period the previous year. There were no customers who represented more than 10% of total billed receivables as of March 31, 2021 or December 31, 2020.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products include components that are currently procured from a single source or a limited number of sources. We believe that other vendors would be able to provide similar components; however, the qualification of such vendors may require start-up time. In order to mitigate any adverse impacts from a disruption of supply, we attempt to maintain an adequate supply of critical limited-source components.</span></div>
CY2020Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2021Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q3 fldm Research And Development Arrangement Contract To Perform For Others Maximum Contract Value
ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue
34000000.0 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-443000 USD
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27488000 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30344000 shares
CY2020Q3 fldm Research And Development Arrangement Contract To Perform For Others Maximum Contract Value
ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue
34000000.0 USD
CY2020Q3 fldm Research And Development Arrangement Contract To Perform For Others Liquidated Damages Percentage
ResearchAndDevelopmentArrangementContractToPerformForOthersLiquidatedDamagesPercentage
0.33
CY2020Q3 fldm Research And Development Arrangement Contract To Perform For Others Liquidated Damages Term
ResearchAndDevelopmentArrangementContractToPerformForOthersLiquidatedDamagesTerm
P6M
CY2021Q1 fldm Research And Development Arrangement Contract To Perform For Others Amount
ResearchAndDevelopmentArrangementContractToPerformForOthersAmount
29936000 USD
CY2020Q4 fldm Research And Development Arrangement Contract To Perform For Others Amount
ResearchAndDevelopmentArrangementContractToPerformForOthersAmount
25436000 USD
CY2021Q1 fldm Research And Development Arrangement Contract To Perform For Others Expenses
ResearchAndDevelopmentArrangementContractToPerformForOthersExpenses
-1951000 USD
CY2020Q4 fldm Research And Development Arrangement Contract To Perform For Others Expenses
ResearchAndDevelopmentArrangementContractToPerformForOthersExpenses
-1488000 USD
CY2021Q1 fldm Deferred Grant Revenue
DeferredGrantRevenue
27985000 USD
CY2020Q4 fldm Deferred Grant Revenue
DeferredGrantRevenue
23948000 USD
CY2021Q1 fldm Deferred Grant Income Current
DeferredGrantIncomeCurrent
5818000 USD
CY2020Q4 fldm Deferred Grant Income Current
DeferredGrantIncomeCurrent
2912000 USD
CY2021Q1 fldm Deferred Grant Income Noncurrent
DeferredGrantIncomeNoncurrent
22167000 USD
CY2020Q4 fldm Deferred Grant Income Noncurrent
DeferredGrantIncomeNoncurrent
21036000 USD
CY2021Q1 fldm Deferred Grant Revenue
DeferredGrantRevenue
27985000 USD
CY2020Q4 fldm Deferred Grant Revenue
DeferredGrantRevenue
23948000 USD
CY2021Q1 fldm Research And Development Arrangement Contract To Perform For Others Amount
ResearchAndDevelopmentArrangementContractToPerformForOthersAmount
29936000 USD
CY2020Q4 fldm Research And Development Arrangement Contract To Perform For Others Amount
ResearchAndDevelopmentArrangementContractToPerformForOthersAmount
25436000 USD
CY2021Q1 fldm Research And Development Arrangement Contract To Perform For Others Funding Received
ResearchAndDevelopmentArrangementContractToPerformForOthersFundingReceived
27436000 USD
CY2020Q4 fldm Research And Development Arrangement Contract To Perform For Others Funding Received
ResearchAndDevelopmentArrangementContractToPerformForOthersFundingReceived
25436000 USD
CY2021Q1 fldm Research And Development Arrangement Receivables
ResearchAndDevelopmentArrangementReceivables
2500000 USD
CY2020Q4 fldm Research And Development Arrangement Receivables
ResearchAndDevelopmentArrangementReceivables
0 USD
CY2021Q1 fldm Research And Development Arrangement Contract To Perform For Others Capital Expenditures
ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures
16100000 USD
CY2021Q1 fldm Up Front And Milestone Payments Maximum
UpFrontAndMilestonePaymentsMaximum
11700000 USD
CY2021Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
2800000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32794000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27617000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32794000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27617000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
21500000 USD
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3900000 USD
CY2021Q1 fldm Contract With Customer Liability Increase From Cash Receipts
ContractWithCustomerLiabilityIncreaseFromCashReceipts
3800000 USD
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
21400000 USD
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
11033000 USD
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
8123000 USD
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
4584000 USD
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2648000 USD
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
26388000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
9465000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
12589000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
12483000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2118000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
711000 USD
CY2021Q1 fldm Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
1423000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
38789000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49744000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68520000 USD
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1016000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1016000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50760000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69536000 USD
CY2021Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
16000 USD
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000.0 USD
CY2021Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9846000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
8292000 USD
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1083000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1214000 USD
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10963000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10183000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
21892000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
19689000 USD
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31854000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31544000 USD
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24707000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23989000 USD
CY2021Q1 us-gaap Construction In Progress Gross
ConstructionInProgressGross
16637000 USD
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
9976000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23784000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17531000 USD
CY2021Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2350000 USD
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
7842000 USD
CY2021Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
3634000 USD
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
3367000 USD
CY2021Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
2709000 USD
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
2578000 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8693000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13787000 USD
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1663000 USD
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1390000 USD
CY2021Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
-150000 USD
CY2020Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
227000 USD
CY2021Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
236000 USD
CY2020Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
162000 USD
CY2021Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1277000 USD
CY2020Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1455000 USD
CY2018Q3 us-gaap Line Of Credit Facility Commitment Fee Amount
LineOfCreditFacilityCommitmentFeeAmount
112500 USD
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q1 fldm Operating Lease Right Of Use Asset Gross
OperatingLeaseRightOfUseAssetGross
41836000 USD
CY2020Q4 fldm Operating Lease Right Of Use Asset Gross
OperatingLeaseRightOfUseAssetGross
41900000 USD
CY2021Q1 fldm Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
4591000 USD
CY2020Q4 fldm Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
3786000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
37245000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
38114000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3025000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2973000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37419000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38178000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
40444000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
41151000 USD
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y7M6D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.120
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.119
CY2021Q1 fldm Cash Cash Equivalents And Short Term Investments Amortized Cost
CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
50760000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
50760000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49744000 USD
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1016000 USD
CY2020Q4 fldm Cash Cash Equivalents And Short Term Investments Amortized Cost
CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
69536000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 USD
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
69536000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68520000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1016000 USD
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5442000 shares
CY2021Q1 fldm Sharebased Compensation Arrangementby Sharebased Payment Award Vesting Restrictions Ownership Percentageof Voting Stock
SharebasedCompensationArrangementbySharebasedPaymentAwardVestingRestrictionsOwnershipPercentageofVotingStock
0.10
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1635000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.33
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
23000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.87
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1612000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.32
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
192000 USD
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1417000 shares
CY2021Q1 fldm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
7.51
CY2021Q1 fldm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne
P5Y9M18D
CY2021Q1 fldm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue
162000 USD
CY2021Q1 fldm Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
195000 shares
CY2021Q1 fldm Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
5.98
CY2021Q1 fldm Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2021Q1 fldm Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
30000 USD
CY2021Q1 us-gaap Share Price
SharePrice
4.52
CY2021Q1 fldm Employee Stock Purchase Plan Offering Period
EmployeeStockPurchasePlanOfferingPeriod
P6M
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.85
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3677000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2366000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1700000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-700000 USD
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment

Files In Submission

Name View Source Status
0001628280-21-009552-index-headers.html Edgar Link pending
0001628280-21-009552-index.html Edgar Link pending
0001628280-21-009552.txt Edgar Link pending
0001628280-21-009552-xbrl.zip Edgar Link pending
exhibit10110q1q2021ng.htm Edgar Link pending
exhibit31110q1q2021ng.htm Edgar Link pending
exhibit31210q1q2021ng.htm Edgar Link pending
exhibit32110q1q2021ng.htm Edgar Link pending
exhibit32210q1q2021ng.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fldm-20210331.htm Edgar Link pending
fldm-20210331.xsd Edgar Link pending
fldm-20210331_cal.xml Edgar Link unprocessable
fldm-20210331_def.xml Edgar Link unprocessable
fldm-20210331_g1.jpg Edgar Link pending
fldm-20210331_htm.xml Edgar Link completed
fldm-20210331_lab.xml Edgar Link unprocessable
fldm-20210331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending